By Gaurav Jain
Baxter India gets CDSCO Nod for Oxiris Filter to Treat COVID-19 Patients
Baxter India has received approval from the Central Drugs Standard Control Organization (CDSCO) under Directorate General of Health Services, Ministry of Health & Family Welfare, India, to use Oxiris Filter. Set for the treatment of COVID-19 patients. Oxiris Blood Purification Filter intended for use in critically ill COVID-19 patients in need of blood. Purification where excessive Inflammatory Mediators are present, i.e., Cytokine Storm release. Oxiris set was earlier used with the Prismaflex Control Unit for patients in need of Blood Purification, including Continuous Renal Replacement.
“The COVID-19 cases in India have been spiraling and putting undue pressure on our healthcare system. This approval has come at a crucial time when such filter sets are much required to ease healthcare providers’ burden. We hope the availability of Oxiris will go a long way in fighting the COVID-19 cases in India. We extend our appreciation to the CDSCO for this approval”, said Ravinder Dang, VP, Commercial Excellence, APAC, and General Manager, India, to Prittle Prattle News. through a Press Release.
During Blood Purification Therapy, the patient’s blood passes through the Oxiris Filter Set, absorbing Inflammatory. Mediators and remove Fluid, Electrolytes, and Uremic Toxins, before returning the patient’s blood to the body. Making it the only filter set that does not necessitate the use of additional devices Renal Replacement Therapy (RRT) or removal of Troublesome Inflammatory Cytokines conveyed to Prittle Prattle News by sharing a Press Release. Oxiris is currently in use across countries in Europe and Asia and has been used for more than ten years to treat thousands of patients. Oxiris has validated for use with Baxter’s leading PrisMax and Prismaflex Systems.
Millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital, surgical, and pharmaceutical products every day. Baxter India has served its mission to save and sustain lives for more than 21 years. We committed to engaging collaboratively with patients, healthcare professionals, and the government and healthcare organizations nationally. In India, with our Commercial HQ in Gurgaon, we also support Baxter’s work in advancing healthcare & pharmaceutical globally with our world-class Research & Development and Information Technology centers in Bangalore and Manufacturing the facility Ahmedabad.
